Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

the write-down of goodwill of $599.4 million recorded in the third quarter of 2008, leaving no goodwill on our books as of December 31, 2008. - As of December 31, 2008, cash, short and long-term investments were $41.4 million and net debt was $535.2 million.

Significant Recent Developments

New Senior Secured Credit Facilities. On March 2, 2009 we announced that we had completed a financing transaction with Wells Fargo Foothill, LLC. The financing includes a delayed draw secured term loan facility of up to $10 million, and a secured revolving credit facility with a borrowing base derived from the value of certain of the Company's finished goods inventory and accounts receivable, providing up to an additional $22.5 million in available credit, subject to certain terms and conditions. Any borrowings outstanding under the term loan and revolving credit facility bear interest ranging from LIBOR + 3.25% to LIBOR +3.75%, with a minimum Base LIBOR Rate of 2.25%. The term loan and the revolving credit facility include certain covenants and restrictions with respect to our operations, require us to maintain certain levels of Adjusted EBITDA and interest coverage ratios, among other terms and conditions, and are secured by the assets of the Company and its Canadian and U.S. subsidiaries. The purpose of the financings is to provide additional liquidity and capital resources for working capital and general corporate purposes.

Financial and Strategic Alternatives Process. During approximately the last eight calendar quarters, our royalty revenue has declined significantly, primarily due to lower than expected royalties derived from sales by our partner Boston Scientific Corporation ("BSC") of TAXUS(R) coronary stent systems. This decline in royalty revenue has significantly impacted our ability to fund our operations and service our debt obligations, and has impacted our liquidity position. During
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... CAMBRIDGE, Mass. and REYKJAVIK, Iceland ... provides comprehensive capabilities for using the genome to create better ... publication of the largest studies of whole-genome data yet undertaken. ... Nature Genetics – are built around ... authored by a team of deCODE scientists led by ...
(Date:3/25/2015)... Researchers at Ancon Medical Inc. have ... enable broader and less invasive screening for cancer, ... breath screen. The Minnesota-based medical device maker will ... Administration (FDA) approval process and is targeting a ... Tagging device. , Ancon Medicals nanoparticle breakthrough comes ...
(Date:3/25/2015)... , March 25, 2015 FDNA®, ... version 4 of Face2Gene, allowing geneticists around ... computers, as well as mobile devices. Face2Gene® facilitates detection ... malformations to present comprehensive and up-to-date genetic references. The ... Genetics Meeting, ACMG 2015, in Salt Lake ...
(Date:3/25/2015)... The global Smart Weapons Market can ... technology, platform, and geography. The various technologies ... infra-red, microwave, global positioning systems, and other ... systems, and inertial navigation systems. , Browse ... spread through 172 Pages and in-depth TOC ...
Breaking Biology Technology:Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3FDNA Releases a Multi-Platform Version of Face2Gene, a Genetic Search and Reference Solution at ACMG 2015 2Smart Weapons Market is Estimate to reach $6.1 Billion by 2020 Worth $6.1 Billion by 2020 - New Report by MarketsandMarkets 2Smart Weapons Market is Estimate to reach $6.1 Billion by 2020 Worth $6.1 Billion by 2020 - New Report by MarketsandMarkets 3
... the Way for the Phase III Clinical Development ... Commercialization of THR-100 in Developing Countries, ... (Euronext,Brussels: THR), a biotechnology company focused on vascular ... transfer to Bharat,Biotech International Limited (Hyderabad, India) for ...
... Inc. (the "Company") (Nasdaq: CMED ), a leading China-based,medical ... products and high intensity focused ultrasound tumor,therapy systems, today announced ... - China Day. Location: ... ...
... 2 Sanofi-aventis announced,today that one year ... STEEPLE,studies confirm clear net clinical benefit for ... for Lovenox(R) vs,Unfractionnated Heparin (UFH). The ... were presented during,hotline sessions at the European ...
Cached Biology Technology:ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 3ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... NY) ─ Researchers at Albert Einstein College of Medicine of ... bacteria that cause tuberculosis (TB), a disease responsible for an ... the March 21 online issue of Nature Chemical Biology ... also prevent resistant TB strains from developing. "This approach ...
... (San Diego, CA) March 18, 2010 GenWay Biotech, ... launched the You Test YouTM Cancer Assessment is expanding this ... to offer the You Test YouTM Cancer Assessment in Greece ... other European nations as well. GenWay currently offers this ...
... RECAN has developed a range of unique and highly ... in the blood which counteract bacteria, viruses or cancerous ... of recombinant proteins which are important components of cellular ... in immunisation and experimental studies. A further key advance ...
Cached Biology News:Einstein researchers discover 2 new ways to kill TB 2Manufacturing antibodies 2Manufacturing antibodies 3
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
... assay kit provides complete components including positive ... of DNA fragmentation in cultured cells and ... labeling of apoptotic cells. Internucleosomal ... in mammalian cells. MBLs ApoDIRECT In Situ ...
... Life Science FLA-5100 imaging system allows imaging ... as 40 x 46cm at a pixel ... system is especially suitable for protein electrophoresis ... analysis for genomics., Fuji s FLA-5100 includes ...
... speed and excellent temperature uniformity. Protocols that ... can be run without any modifications. The ... for 48 or 96 wells. In addition, ... applications are available. The High Precision Smart ...
Biology Products: